Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24824267 | 0.87 | HTT (0.42) | HTTLMNAALDH1A1PLA2G2CCYP2C9 | |
| SCHEMBL20227110 | 0.86 | USP2 (0.41) | USP2HTTLMNAALDH1A1THRB | |
| SCHEMBL11953067 | 0.84 | USP2 (0.39) | USP2LMNAALDH1A1 | |
| SCHEMBL100711 | 0.82 | USP2 (0.42) | USP2LMNAALDH1A1 | |
| SCHEMBL21895581 | 0.82 | THRB (0.39) | HTTPLA2G2CCYP2C9TSHRCYP2C19 | |
| SCHEMBL18609453 | 0.81 | PLA2G2C (0.39) | USP2HTTPLA2G2CCYP2C9TSHR | |
| SCHEMBL9873342 | 0.81 | PLA2G2C (0.39) | USP2HTTPLA2G2CCYP2C9TSHR | |
| SCHEMBL9873857 | 0.81 | HTT (0.38) | HTTLMNAPLA2G2C | |
| SCHEMBL15494110 | 0.80 | USP2 (0.37) | USP2LMNAALDH1A1 | |
| SCHEMBL21633295 | 0.80 | USP2 (0.37) | USP2HTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3635022-B1 | METHODS FOR MAKING FUNCTIONALIZED FLUORINATED MONOMERS, FLUORINATED MONOMERS, AND COMPOSITIONS FOR MAKING THE SAME | ETNA TEC LTD (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-116354830-A | Process for the preparation of functionalized fluorinated monomers, fluorinated monomers and compositions for the preparation thereof | 埃特纳科技有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-110770271-B | Method for preparing functionalized fluorinated monomers, fluorinated monomers and compositions for preparing same | 埃特纳科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-11492318-B2 | Methods for making functionalized fluorinated monomers, fluorinated monomers, and compositions for making the same | ETNA-TEC, LTD. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220213016-A1 | Methods for Making Functionalized Fluorinated Monomers, Fluorinated Monomers, and Compositions for Making the Same | ETNA-TEC, LTD. | 2022-07-07 | — | — | US | disclosed |
| EP-3635022-A1 | METHODS FOR MAKING FUNCTIONALIZED FLUORINATED MONOMERS, FLUORINATED MONOMERS, AND COMPOSITIONS FOR MAKING THE SAME | Etna-Tec, Ltd (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200102417-A1 | STRETCHABLE FILM AND METHOD FOR FORMING STRETCHABLE FILM | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-04-02 | — | — | US | disclosed |
| CN-110770271-A | Method for preparing functionalized fluorinated monomers, fluorinated monomers and compositions for preparing same | 埃特纳科技有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200040125-A1 | STRETCHABLE FILM AND METHOD FOR FORMING THE SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-02-06 | — | — | US | disclosed |
| US-20180334417-A1 | Methods for Making Functionalized Fluorinated Monomers, Fluorinated Monomers, and Compositions for Making the Same | ETNA-TEC, LTD. | 2018-11-22 | — | — | US | disclosed |
| US-20070148682-A1 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-7169829-B2 | Maleimido-bearing compounds resin composition containing the same and cured articles thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-7160691-B2 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY THERA INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6929916-B2 | Protein fragment complementation assays for the detection of biological or drug interactions | ODYSSEY THERA INC. (US) | 2005-08-16 | — | — | US | disclosed |
| US-20050079547-A1 | Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy | MICHNICK STEPHEN WILLIAM WATSO (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050009947-A1 | Maleimido-bearing compounds resin composition containing the same and cured articles thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1460092-A1 | MALEIMIDO-BEARING COMPOUNDS, RESIN COMPOSITIONS CONTAINING THE SAME AND CURED ARTICLES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6294330-B1 | SCREENING LIGANDS OF CELLULAR RECEPTOR BY GENERATING VECTORS ENCODING FUSION PROTEINS OF FRAGMENTS OF REPORTER MOLECULE AND SUBDOMAINS OF RECEPTOR, TRANSFECTING CELLS WITH VECTORS, TESTING CELLS FOR REPORTER MOLECULE ACTIVITY | ODYSSEY PHARMACEUTICALS INC. | 2001-09-25 | — | — | US | disclosed |
| US-6270964-B1 | POLYPEPTIDE USED A DIAGNOSTIC TOOL IN GENETIC ENGINEERING | ODYSSEY PHARMACEUTICALS INC. | 2001-08-07 | — | — | US | disclosed |
| EP-0254540-A2 | Glycerol derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334417-A1 | Methods for Making Functionalized Fluorinated Monomers, Fluorinated Monomers, and Compositions for Making the Same | ALKBH3, FTO, THEM6 | USP2 2523/4885HTT 2042/4885LMNA 1217/4885 |
| US-20220213016-A1 | Methods for Making Functionalized Fluorinated Monomers, Fluorinated Monomers, and Compositions for Making the Same | ALKBH3, FTO, ALK | USP2 2470/4885HTT 2018/4885LMNA 1234/4885 |
| US-11492318-B2 | Methods for making functionalized fluorinated monomers, fluorinated monomers, and compositions for making the same | ALKBH3, FTO, ALK | USP2 2470/4885HTT 2018/4885LMNA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.